Companies › Arsenal Biosciences
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AB-2100 Integrated Circuit T cell therapy; autologous T cells engineered with synthetic immunologi | – | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Dec 2026 |
| AB-3028 Programmable circuit autologous T cell therapy | – | Phase 1 | Metastatic Castration Resistant Prostate Cancer (mCRPC) | May 2029 |
| AB-1015 Integrated Circuit T (ICT) cells; autologous T cell therapy | – | Phase 1 | Carcinoma, Ovarian Epithelial | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05617755 | AB-1015 | Phase 1 | Carcinoma, Ovarian Epithelial | Oncology | Sep 2024 |
| NCT06245915 | AB-2100 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT07285694 | AB-3028 | Phase 1 | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Oncology | May 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.